KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Inventory: 2010-2025

Historic Inventory for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $356.3 million.

  • Emergent BioSolutions' Inventory rose 10.41% to $356.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $356.3 million, marking a year-over-year increase of 10.41%. This contributed to the annual value of $311.7 million for FY2024, which is 5.23% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Inventory is $356.3 million, which was up 5.23% from $338.6 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Inventory high stood at $528.2 million for Q3 2022, and its period low was $311.7 million during Q4 2024.
  • Moreover, its 3-year median value for Inventory was $333.4 million (2024), whereas its average is $336.3 million.
  • Per our database at Business Quant, Emergent BioSolutions' Inventory spiked by 63.85% in 2021 and then slumped by 32.96% in 2023.
  • Emergent BioSolutions' Inventory (Quarterly) stood at $344.5 million in 2021, then climbed by 1.80% to $350.7 million in 2022, then declined by 6.22% to $328.9 million in 2023, then fell by 5.23% to $311.7 million in 2024, then climbed by 10.41% to $356.3 million in 2025.
  • Its last three reported values are $356.3 million in Q3 2025, $338.6 million for Q2 2025, and $314.0 million during Q1 2025.